Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIA2 | P42262 | 9/20 | 0.60 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.57 |
| ▸ | KIF11 | P52732 | 1/20 | 0.49 |
| ▸ | KDM1A | O60341 | 3/20 | 0.48 |
| ▸ | TDP2 | O95551 | 2/20 | 0.43 |
| ▸ | BRD4 | O60885 | 1/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.41 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.41 |
| ▸ | FPR2 | P25090 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6243992 | 0.94 | GRIA2 (0.58) | GRIA2KCNH2KIF11KDM1ATDP2 | |
| SCHEMBL6246774 | 0.85 | GRIA2 (0.60) | GRIA2KCNH2KDM1ACYP3A4AAK1 | |
| SCHEMBL6243805 | 0.84 | GRIA4 (0.44) | GRIA2KCNH2KDM1ACYP1A2 | |
| SCHEMBL6245808 | 0.83 | CA12 (0.41) | GRIA2KCNH2KDM1ACYP1A2 | |
| SCHEMBL6239376 | 0.83 | KIF11 (0.47) | GRIA2KCNH2KIF11KDM1ATDP2 | |
| SCHEMBL6236864 | 0.80 | ADAMTS4 (0.46) | GRIA2KCNH2 | |
| SCHEMBL6239212 | 0.79 | GRIA2 (0.58) | GRIA2KCNH2KDM1ACYP3A4AAK1 | |
| SCHEMBL8028031 | 0.77 | GRIA2 (0.65) | GRIA2KCNH2KIF11KDM1ATDP2 | |
| SCHEMBL6243998 | 0.77 | KIF11 (0.46) | GRIA2KCNH2KIF11KDM1ATDP2 | |
| SCHEMBL6239207 | 0.77 | GRIA4 (0.44) | GRIA2KCNH2CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1395550-B1 | CYCLOALKENYLSULFONAMIDE DERIVATIVES | LILLY CO ELI (US) | 2005-06-29 | — | — | EP | disclosed |
| US-20040157817-A1 | Cycloalkenylsulfonamide derivatives | CANTELL BUDDY EUGENE (US) | 2004-08-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040157817-A1 | Cycloalkenylsulfonamide derivatives | GRIN2B, GRIN2A, GRIN1 | GRIA2 7/4885KCNH2 552/4885KIF11 2947/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.